ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 144 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $876,150 | -68.6% | 165,000 | -43.6% | 0.50% | -67.9% |
| Q2 2023 | $2,787,525 | +33.4% | 292,500 | +53.9% | 1.55% | +7.3% |
| Q1 2023 | $2,090,000 | +79.9% | 190,000 | +142.0% | 1.44% | +25.6% |
| Q4 2022 | $1,161,800 | +6.7% | 78,500 | +49.5% | 1.15% | +262.1% |
| Q4 2021 | $1,089,000 | +28.4% | 52,500 | +47.9% | 0.32% | +46.8% |
| Q3 2021 | $848,000 | +130.4% | 35,500 | +163.0% | 0.22% | +116.0% |
| Q2 2021 | $368,000 | +6.1% | 13,500 | +12.5% | 0.10% | -14.5% |
| Q1 2021 | $347,000 | – | 12,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |